Obesity-induced hypoadiponectinaemia:the opposite influences of central and peripheral fat compartments by Borges, Carolina et al.
                          Borges, C., Oliveira, I. O., Freitas, D. F., Horta, B. L., Ong, K. K., Gigante,
D. P., & Barros, A. J. D. (2017). Obesity-induced hypoadiponectinaemia: the
opposite influences of central and peripheral fat compartments. International
Journal of Epidemiology, [dyx022]. DOI: 10.1093/ije/dyx022
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1093/ije/dyx022
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Oxford University
Press at https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyx022 Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
SUPPLEMENTARY MATERIAL  
SUPPLEMENTARY METHODS 
 
1982 Pelotas Birth Cohort – Conventional association analysis 
 
Body composition and anthropometric measures 
Abdominal fat depots were measured using the ultrasound machine Toshiba Xario (Toshiba 
Medical Systems Corp., Tokyo, Japan)1-3. Briefly, visceral fat thickness was estimated by the distance 
between the peritoneum and the lumbar spine at the intersection between the xyphoid line and the waist 
circumference. Subcutaneous abdominal fat thickness was estimated at the same probe site by the distance 
between the posterior line of dermis and the outer bowel wall. Intra-observer error was 4.1% for visceral 
and 3.4% for subcutaneous abdominal fat. Inter-observer technical error of measurement was 3.1% for both 
visceral fat and subcutaneous abdominal fat. Women that were pregnant or three months postpartum were 
excluded.  
Gluteofemoral fat was assessed by Dual-energy X-ray Absorptiometry (DXA) (Lunar Prodigy 
Advance—GE, Germany). Participants with osteoarticular disabilities, confirmed or suspected pregnancy, 
non-removable metallic objects, wheelchair users, extremely obese (weight > 120 kg) or extremely tall 
(height > 192 cm) individuals were excluded. Weight was measured to the nearest 0.1 kg on a calibrated 
electronic scale (TANITA model BC‐418 MA; Tanita, Tokyo, Japan).  
Standing height was assessed to the nearest 0.1 cm using a full‐length wall‐mounted stadiometer 
(SECA 240; Seca, Birmingham, United Kingdom).  
 
Genomic ancestry 
Genomic ancestry was estimated using 370,539 ancestry informative markers shared by samples 
from the HapMap Project 4, the Human Genome Diversity Project (HGDP) 5 and the Epigen-Brazil study 
population 6. The following HapMap samples were used: 266 Africans (176 Yoruba in Ibadan, Nigeria 
[YRI] and 90 Luhya in Webuye, Kenya [LWK]), 262 Europeans (174 Utah residents with Northern and 
Western European ancestry [CEU] and 88 from Toscans from Italy [TSI]), 170 admixed individuals (77 
Mexicans from Los Angeles, California [MEX] and 83 Afro-African from Southwest USA [ASW]), and 
93 Native Americans from the HGDP (25 Pima, 22 Karitiana, 25 Maya and 21 Surui). The software 
ADMIXTURE 7 was used to estimate the contribution from European, African and Native American 
ancestry for each cohort participant. SNPs were genotyped using Illumina Omni 2.5M-8v1 array (San 
Diego, California). Further details can be found in Lima-Costa et al. 6. 
 
GIANT and ADIPOGen consortia – Mendelian randomization analysis 
 
Proportion of phenotypic variance explained by genetic instruments 
 In order to estimate the strength of our genetic instruments, we estimated the phenotypic variance 
explained by a given SNP (R2) for each exposure of interest (waist circumference, hip circumference, and 
adiponectin concentration). We used ADIPOGen and GIANT summary data to approximate R2 for a given 
SNP based on the effect estimate for its association with the trait of interest (beta or ?̂?), respective standard 
error (𝑠𝑒(?̂?)), minor allele frequency (MAF), and sample size (N). The following formula was used as 
previously described by Shim et al., 20158: 
 
𝑅2  ≅  
2?̂?2𝑀𝐴𝐹(1 − 𝑀𝐴𝐹)
2?̂?2𝑀𝐴𝐹(1 − 𝑀𝐴𝐹) + (𝑠𝑒(?̂?))22𝑁𝑀𝐴𝐹(1 − 𝑀𝐴𝐹) 
  
 
The phenotypic variance explained by the composite genetic instrument (combining all SNPs) was 
estimated by the sum of SNP-specific R2.  
 
Power calculations 
 We have estimated power for our Mendelian randomization analyses using the online calculator 
tool (http://cnsgenomics.com/shiny/mRnd/) and assuming a range of effect sizes for the potential 
underlying causal association between exposure and outcome. Details on the parameters used and the 
resulting estimated power are provided below. 
 
Exposure Outcome Sample size1 Type-I 
error rate 
Effect 
estimate2 
Instrument 
strength (R2)3 
Power 
WC Adiponectin 29,347 0.05 0.05 0.012 16% 
WC Adiponectin 29,347 0.05 0.10 0.012 47% 
WC Adiponectin 29,347 0.05 0.20 0.012 97% 
HipC Adiponectin 29,347 0.05 0.05 0.02 23% 
HipC Adiponectin 29,347 0.05 0.10 0.02 68% 
HipC Adiponectin 29,347 0.05 0.20 0.02 100% 
Adiponectin WC or HipC 210,088 0.05 0.05 0.04 100% 
Adiponectin WC or HipC 210,088 0.05 0.10 0.04 100% 
Adiponectin WC or HipC 210,088 0.05 0.20 0.04 100% 
1 Approximate sample size used for estimating SNP-outcome association 
2 Considering the true underlying causal association is unknown, a range of values was used. 
3 Instrument strength relates to the proportion of variance in the exposure explained by the instrument (R2). 
This was calculated by the sum of R2 from each SNP in the instrument (56 SNPs for waist circumference, 
75 SNPs for hip circumference and 4 SNPs for adiponectin concentration). SNPs were in linkage 
equilibrium. The formula used to estimate R2 for each SNP is detailed in “Proportion of phenotypic variance 
explained by genetic instruments” section. 
 
Inverse-variance weighted (IVW) method 
For the unadjusted Mendelian randomization model, the inverse-variance weighted (IVW) method 
was used to derive the beta coefficient (mean difference in standardized log adiponectin per standard unit 
increase in waist or hip circumference) and its standard error by using the following formulas: 
 
?̂?IVW =  
∑ 𝑋𝑘𝑌𝑘
𝐾
𝑘=1 𝜎𝑦𝑘
−2
∑ 𝑋𝑘
2𝜎𝑦𝑘
−2 𝐾𝑘=1
                        𝑆𝐸?̂?IVW =   √
1
∑ 𝑋𝑘
2𝜎𝑦𝑘
−2 𝐾𝑘=1
 
 
Where Xk is the mean difference in standardized waist or hip circumference per additional effect 
allele of SNP k and Yk is the mean difference in standardized log adiponectin per additional effect allele of 
SNP k with standard error σYk.   
For the adjusted Mendelian randomization model, we fitted a model having betas for SNP-
adiponectin levels association as the dependent variable, betas for SNP-waist circumference and SNP-hip 
circumference as independent variables and inverse variance weights (with no intercept) to estimate the 
independent association of genetically increased waist or hip circumference with blood adiponectin levels. 
This method is equivalent to the unadjusted IVW method when there is only one independent variable 9. 
In the original ADIPOGen summary dataset, betas for the association of SNPs with adiponectin 
concentration are provided as changes in log units of adiponectin per SNP allele. In order to have the same 
scale between Mendelian randomization and conventional association analysis, betas (and standard errors) 
from ADIPOGen dataset had to be harmonised prior to analysis. As only summary data was available, 
conversion of log adiponectin to equivalent standardized log adiponectin was made using individual level 
data from 1982 Pelotas Birth Cohort with similar adiponectin distribution (adiponectin levels in ADIPOGen 
consortium: mean = 9.8 μg/ml (SD = 5.6); adiponectin levels in 1982 Pelotas Birth Cohort: mean = 9.3 
μg/ml (SD = 5.7)).  
 
MR-Egger regression method 
The Egger regression has been used for almost two decades to detect small study bias in meta-
analyses of randomized clinical trials 10. In this method, the ratio of the effect estimate by its standard error 
is regressed against the estimate’s precision (the inverse of the standard error). Bowden et al. 11 recently 
proposed an adaptation of the Egger regression to test for bias from pleiotropy in Mendelian randomisation 
studies. 
While the IVW estimate is equivalent to the slope of the best fitting line through the observations 
that pass through the origin, the MR-Egger estimate would be the of the best fitting line through the 
observations in a model that allows the intercept to vary. In this method, the intercept will reflect the average 
pleiotropic effect across genetic variants (e.g. mean difference in log adiponectin levels when difference in 
waist or hip circumference per allele is zero) and the slope coefficient will provide an estimate of the causal 
effect provided that the InSIDE (Instrument Strength Independent of Direct Effect) assumption holds, 
which requires that there is no correlation between SNP-exposure association and direct effects of SNP on 
outcome. The MR-Egger estimate may be underpowered, as it relies on variants having different strengths 
of association with the risk factor. Bootstrapping (10,000 iterations) was used to derive corrected 95% 
confidence intervals for MR-Egger intercept and slope using the percentile method 11. 
 
Penalized weighted median estimator 
Median-based methods give consistent estimates even when up to half the genetic variants are 
invalid instrumental variables. The weighted median estimate is defined as the median of an empirical 
distribution in which each instrumental variable estimate appears with probability proportional to the 
inverse of its variance12. The weighted median estimate is consistent under the assumption that genetic 
variants representing over 50% of the weight in the analysis are valid instruments. The contribution of 
heterogeneous variants to the weighted median estimate was downweighted (penalized) by multiplying the 
inverse-variance weight by the p-value of a chi-squared distribution (1 degree of freedom) corresponding 
to the Q statistics of each SNP when p-value < 0.05 13. Bootstrapping (1,000 iterations) was carried out and 
the bootstrap standard error (the standard deviation of the bootstrap estimates) and a normal approximation 
(estimate ± 1.96*standard error) were used to derive 95% confidence interval 13. 
 
  
SUPPLEMENTARY TABLES AND FIGURES 
 
Supplementary table 1. Core instrumental variable assumptions and strategies used to address them 
Assumption Graphical examples of 
assumption violation* 
Consequences of potential 
violation 
Validation of assumption in the current 
analysis 
 
1. IV should be 
(strongly) 
associated 
with the 
exposure 
 
 
 
 
A weak association between the 
IV and E can reduce precision 
and introduce weak instrument 
bias, which tends to bias the 
causal estimate towards the OLS 
estimate in one-sample MR 
- Only genetic variants strongly associated 
with the exposure were selected  
 
- In two-sample MR studies with non-
overlapping datasets, any bias from weak 
instruments would be in the direction of the 
null and, thus, should not result in false 
positive findings 
 
 
 
 
 
2. IV should only 
affect the 
outcome 
through the 
exposure 
 
 
 
 
 
 
 
 
 
 
Bias in MR estimate can result 
from horizontal pleiotropy (e.g. 
genetic variant itself or a 
correlated variant is associated 
with multiple pathways 
independent of the exposure) the 
direction and magnitude of this 
bias will depend up the direction 
and magnitude of the association 
path from IV to O that is not via 
E 
 
 
 
 
- We extensively investigated heterogeneity 
and asymmetry in IVW estimates 
 
- We compared results from the conventional 
Mendelian randomization analysis to other 
Mendelian randomization estimators 
(Penalized weighted median estimator MR-
Egger method) based on a less stringent set 
of assumptions to assess the validity of our 
findings 
3. IV should be 
independent of 
exposure-
outcome 
confounders 
and IV-
outcome 
exposures 
 
 
 
In cases of population 
stratification, there could be an 
spurious association between IV 
and phenotypes 
- To reduce the possibility of bias due to 
population stratification, the analyses were 
restricted to European-ancestry individuals 
 
- All consortia accounted for population 
structure by adjusting for genomic control 
inflation factor 
IV: instrumental variable; E: exposure; O: outcome; U: unknown confounder; X: other phenotype: G: other genetic 
variant in LD; LD: linkage disequilibrium. A dashed arrow was used to indicate weak association between IV and 
E. Adapted from Vanderweele.14 
 
Supplementary Table 2. Characteristics of data sources used in the Mendelian randomization analyses 
Consortium ADIPOGen GIANT 
Use SNP-log adiponectin* SNP-BMI-adjusted WC and SNP-BMI-adjusted HipC 
Studies 16 cohort studies with GWAS data 101 studies of multiple designs with GWAS or Metabochip data 
Study population 29,347 individuals of European ancestry ≈ 210,088 individuals of European ancestry 
Study-specific mean age (in years) - median 
[range] 
52 [10, 75] 58 [19, 76] 
Study-specific mean adiponectin levels 
(µg/mL) - median [range] 
9.8 [4.9, 15.8] N/A 
Study-specific median WC (in cm) - median 
[range] 
N/A 101 [75, 116] 
Study-specific median HipC (in cm) - 
median [range] 
N/A 96 [63, 119] 
Imputation 
IMPUTE, MACH, BIMBAM or Beagle (reference: Phase II 
CEU HapMap population) 
IMPUTE, MACH or Beagle (reference: Phase II CEU HapMap 
population) 
Quality control criteria† 
Call rate > 0·95; MAF > 0·01; p HWE > 10-6; and quality 
measures for imputed SNPs (r2 ≥ 0·3, or proper info ≥ 0·4) 
Sample cal rate > 0·85-0·98; SNP call rate > 0·90-0·99; MAF > 
0·00-0·01; p HWE > 10-3-10-7; and quality measures for imputed SNPs 
(r2 ≥ 0·3, proper info ≥ 0·4, or no filtering) 
Model additive additive 
Adjustments 
Age, sex, BMI, principal components of genomic ancestry, 
study site (where appropriate), family structure (one family-
based study) and genomic control inflation factor (λ) 
Age, age2, BMI and study specific variables (e.g. principal 
components of genomic ancestry), and genomic control inflation 
factor (λ) 
Data download https://www.mcgill.ca/genepi/adipogen-consortium 
http://www.broadinstitute.org/collaboration/giant/index.php/GIANT
_consortium_data_files 
* Blood adiponectin concentration was assessed using ELISA or RIA methods. † Quality control criteria may have varied across studies within each consortium. BMI: body mass index; CEU: 
Centre d’Etude du Polymorphisme Humain collected in Utah; GIANT: Genetic Investigation of ANthropometric Traits; GWAS: genome-wide association study; HipC: hip circumference; HWE: 
Hardy-Weinberg equilibrium; MAF: minor allele frequency; SNP: single nucleotide polymorphism; WC: waist circumference; N/A: not available. Information on study-specific age, adiponectin 
levels, WC, and HipC distribution were extracted from the supplementary material of the original publications of GIANT15 and ADIPOGen16. Medians were calculated based only on studies for 
which information was available in the original publications (all the 16 cohorts from ADIPOGen and 91 out of 101 studies from GIANT) 
Supplementary Table 3. SNPs used as instrumental variables for waist circumference in Mendelian 
randomization analysis 
rs ID Chr EA NEA EAF R2 Beta SE P-value N 
rs9435732 1 C T 0.825 0.0003 0.031 0.004 4E-16 228579 
rs7536458 1 T G 0.65 0.0003 0.030 0.004 1E-15 228790 
rs12064744 1 T C 0.3417 0.0002 0.026 0.004 2E-14 231298 
rs984222 1 G C 0.575 0.0005 0.036 0.004 2E-25 231215 
rs11205277 1 G A 0.3898 0.0003 0.027 0.004 1E-13 215898 
rs2274432 1 A G 0.3729 0.0002 0.025 0.004 2E-12 227843 
rs12991495 2 T C 0.675 0.0002 0.028 0.004 6E-14 229964 
rs6715793 2 T C 0.45 0.0001 0.019 0.003 1E-08 231071 
rs2052670 2 G A 0.4083 0.0001 0.020 0.004 2E-08 231210 
rs2124969 2 C T 0.4083 0.0001 0.020 0.003 7E-09 231284 
rs13083798 3 A G 0.5417 0.0002 0.020 0.003 3E-09 230391 
rs9864077 3 T C 0.7583 0.0002 0.022 0.004 1E-09 219478 
rs6772896 3 T C 0.6417 0.0002 0.024 0.004 2E-11 231246 
rs7621331 3 A G 0.6917 0.0001 0.021 0.004 9E-09 231264 
rs1344674 3 G A 0.4833 0.0002 0.024 0.003 4E-13 231241 
rs17451107 3 T C 0.625 0.0002 0.026 0.004 1E-13 227636 
rs12493901 3 G A 0.5417 0.0002 0.021 0.003 8E-10 230668 
rs710841 4 T C 0.2417 0.0003 0.029 0.004 9E-14 230174 
rs17541471 5 C T 0.2333 0.0001 0.023 0.004 4E-08 230478 
rs12656497 5 T C 0.4833 0.0002 0.022 0.003 2E-10 231223 
rs459193 5 A G 0.2167 0.0002 0.025 0.004 8E-11 231220 
rs10041657 5 A G 0.2167 0.0002 0.025 0.004 3E-10 230824 
rs272869 5 G A 0.6583 0.0002 0.021 0.003 7E-10 229935 
rs4868125 5 G C 0.6417 0.0002 0.021 0.004 3E-09 225860 
rs10516107 5 A G 0.2917 0.0002 0.023 0.004 8E-11 231310 
rs6556301 5 T G 0.375 0.0003 0.028 0.004 2E-12 191245 
rs1776897 6 G T 0.075 0.0004 0.061 0.007 6E-20 197374 
rs998584 6 A C 0.475 0.0003 0.029 0.004 6E-15 210814 
rs395962 6 T G 0.3667 0.0003 0.029 0.004 1E-15 231306 
rs2745359 6 C T 0.069 0.0002 0.052 0.009 2E-09 178085 
rs2745353 6 T C 0.55 0.0003 0.029 0.003 8E-19 231143 
rs6570507 6 G A 0.75 0.0002 0.024 0.004 6E-11 228993 
rs798489 7 C T 0.725 0.0002 0.025 0.004 1E-11 230932 
rs2214442 7 G A 0.4417 0.0002 0.026 0.005 4E-09 152053 
rs4141278 7 C T 0.1833 0.0003 0.034 0.004 3E-15 231233 
rs7801581 7 T C 0.2583 0.0002 0.027 0.004 8E-11 216463 
rs849140 7 T C 0.4 0.0003 0.029 0.003 5E-17 228910 
rs12679556 8 G T 0.2083 0.0002 0.026 0.004 1E-11 225056 
rs7854560 9 T C 0.2667 0.0002 0.026 0.004 5E-12 229674 
rs10748826 10 T C 0.5776 0.0002 0.023 0.004 3E-10 195019 
rs2071449 12 A C 0.325 0.0003 0.032 0.004 3E-18 226567 
rs7970350 12 C T 0.5083 0.0001 0.019 0.003 4E-08 229815 
rs12317176 12 T C 0.6167 0.0001 0.020 0.004 6E-09 230924 
rs12372180 12 A G 0.0667 0.0001 0.041 0.007 3E-08 219175 
rs7166081 15 A G 0.8083 0.0002 0.024 0.004 2E-09 230255 
rs4886782 15 G A 0.7333 0.0002 0.024 0.004 6E-12 228446 
rs4246302 15 G A 0.3333 0.0002 0.022 0.004 6E-09 227205 
rs4567683 15 A G 0.2833 0.0001 0.022 0.004 8E-09 228589 
rs16957304 16 A G 0.95 0.0002 0.059 0.011 3E-08 151917 
rs3760318 17 G A 0.6417 0.0002 0.021 0.004 9E-10 228998 
rs757608 17 A G 0.3 0.0002 0.027 0.004 1E-13 229039 
rs4239436 18 G A 0.7417 0.0004 0.040 0.004 1E-22 229607 
rs12608504 19 A G 0.3417 0.0001 0.020 0.004 2E-08 228998 
rs3786897 19 G A 0.4083 0.0001 0.020 0.004 9E-09 228567 
rs979012 20 T C 0.3583 0.0004 0.033 0.004 5E-20 229815 
rs2179129 22 A G 0.55 0.0001 0.019 0.003 3E-08 228844 
 Chr: chromosome; EA: effect allele (trait-increasing allele); NEA: non-effect allele; R2: proportion of 
phenotypic variance explained by SNP; Beta: increase in standardized waist circumference per EA; SE: 
standard error; N: sample size.  
Supplementary Table 4. SNPs used as instrumental variables for hip circumference in Mendelian 
randomization analysis 
rs ID Chr EA NEA EAF R2 Beta SE P-value N 
rs6657613 1 T A 0.53 0.0004 0.031 0.004 4E-18 210917 
rs12086130 1 T C 0.10 0.0002 0.037 0.006 3E-09 206610 
rs3748656 1 C T 0.80 0.0002 0.024 0.004 6E-09 210890 
rs11205303 1 C T 0.36 0.0005 0.041 0.004 6E-25 196314 
rs17346473 1 G A 0.22 0.0003 0.030 0.004 3E-14 210431 
rs12075079 1 G A 0.16 0.0002 0.031 0.004 5E-13 211016 
rs2301453 1 A G 0.54 0.0002 0.022 0.004 6E-10 210882 
rs1046934 1 C A 0.38 0.0002 0.023 0.004 6E-10 210450 
rs2820443 1 C T 0.30 0.0007 0.048 0.004 2E-35 211030 
rs6672530 1 A C 0.77 0.0002 0.028 0.005 8E-10 208172 
rs1545552 2 G A 0.71 0.0003 0.029 0.004 6E-13 208132 
rs10195252 2 C T 0.44 0.0002 0.023 0.004 1E-10 210403 
rs4973517 2 T C 0.75 0.0002 0.029 0.005 2E-10 175930 
rs11242 3 T C 0.43 0.0003 0.027 0.004 6E-14 204637 
rs1388251 3 A G 0.74 0.0002 0.023 0.004 2E-08 211029 
rs10804591 3 C A 0.15 0.0004 0.038 0.004 7E-18 210953 
rs724016 3 G A 0.48 0.0009 0.048 0.004 8E-43 211032 
rs4243400 3 G A 0.50 0.0002 0.025 0.004 3E-12 210478 
rs2098771 3 G A 0.33 0.0001 0.022 0.004 4E-08 196732 
rs6845078 4 C T 0.84 0.0002 0.035 0.005 9E-12 207534 
rs9993613 4 T G 0.51 0.0003 0.027 0.005 7E-10 143494 
rs1662837 4 C T 0.28 0.0003 0.028 0.004 1E-13 210825 
rs12648786 4 A G 0.41 0.0003 0.032 0.004 2E-16 199289 
rs11736535 4 G A 0.30 0.0003 0.029 0.005 1E-10 143695 
rs11730399 4 A C 0.95 0.0003 0.060 0.008 5E-13 173372 
rs1173771 5 A G 0.47 0.0002 0.026 0.004 6E-13 210986 
rs7703857 5 T C 0.41 0.0003 0.028 0.005 5E-10 143721 
rs1294410 6 T C 0.38 0.0003 0.029 0.004 2E-15 210861 
rs13216391 6 G A 0.15 0.0002 0.028 0.005 3E-09 199240 
rs11754288 6 A G 0.47 0.0002 0.021 0.004 3E-09 210954 
rs12210905 6 A G 0.88 0.0002 0.033 0.006 1E-08 210929 
rs1759645 6 C T 0.13 0.0002 0.029 0.005 9E-09 209671 
rs16894959 6 C T 0.10 0.0002 0.036 0.005 3E-13 210242 
rs975496 6 G A 0.84 0.0002 0.031 0.005 1E-09 199331 
rs6903448 6 C T 0.84 0.0002 0.034 0.005 5E-12 211031 
rs12207675 6 C T 0.13 0.0003 0.041 0.006 1E-13 211077 
rs7759938 6 C T 0.36 0.0003 0.028 0.004 2E-13 211029 
rs1538170 6 T C 0.38 0.0002 0.026 0.004 3E-12 201926 
rs9491696 6 C G 0.47 0.0002 0.023 0.004 1E-10 210813 
rs9388766 6 T C 0.33 0.0002 0.028 0.004 8E-13 211072 
rs6570509 6 G T 0.74 0.0006 0.045 0.004 1E-29 197803 
rs798497 7 A G 0.72 0.0004 0.035 0.004 4E-20 210942 
rs849141 7 A G 0.29 0.0003 0.032 0.004 2E-16 211081 
rs42235 7 T C 0.34 0.0004 0.036 0.004 8E-20 208455 
rs3731321 7 T C 0.87 0.0002 0.029 0.005 5E-08 182525 
rs7008867 8 A G 0.21 0.0002 0.024 0.004 6E-09 211066 
rs10958476 8 C T 0.14 0.0002 0.028 0.005 9E-10 199716 
rs6984782 8 T C 0.88 0.0002 0.033 0.005 2E-09 210592 
rs6470764 8 C T 0.81 0.0004 0.039 0.005 8E-18 210864 
rs7007820 8 A G 0.63 0.0001 0.020 0.004 1E-08 211016 
rs4448343 9 G A 0.32 0.0002 0.024 0.004 3E-11 210984 
rs10123368 9 C T 0.20 0.0002 0.026 0.004 5E-09 210933 
rs686320 11 G C 0.91 0.0002 0.038 0.006 7E-12 199308 
rs1351394 12 T C 0.48 0.0002 0.025 0.004 5E-13 210068 
rs10748128 12 T G 0.36 0.0002 0.023 0.004 4E-09 197305 
rs7953508 12 T C 0.25 0.0002 0.024 0.004 4E-09 210624 
rs12817549 12 T C 0.57 0.0003 0.029 0.004 2E-16 210856 
rs1727294 12 A G 0.20 0.0003 0.032 0.004 8E-14 208707 
rs3118906 13 G A 0.76 0.0003 0.030 0.004 8E-15 211005 
rs558003 13 A G 0.04 0.0003 0.049 0.006 4E-15 199267 
rs10140922 14 G T 0.63 0.0003 0.030 0.005 5E-11 143568 
rs1254263 14 C T 0.28 0.0003 0.029 0.005 9E-10 143808 
rs17193922 16 G C 0.38 0.0002 0.024 0.004 1E-09 198589 
rs9890032 17 C G 0.63 0.0002 0.026 0.004 2E-12 207385 
rs561341 17 G T 0.17 0.0002 0.031 0.005 3E-10 211106 
rs7223966 17 A G 0.32 0.0003 0.029 0.004 2E-13 211080 
rs1120297 17 T C 0.48 0.0002 0.021 0.004 2E-09 210991 
rs4369779 18 C T 0.74 0.0003 0.035 0.004 3E-15 210787 
rs181553 18 A G 0.68 0.0003 0.029 0.004 9E-15 210832 
rs12980348 19 G T 0.38 0.0003 0.029 0.004 9E-16 210456 
rs169797 20 A G 0.75 0.0002 0.024 0.004 1E-09 204594 
rs6088619 20 G A 0.13 0.0003 0.039 0.005 9E-13 199166 
rs143384 20 G A 0.40 0.0006 0.044 0.004 1E-31 209682 
rs6060717 20 C T 0.16 0.0002 0.032 0.005 6E-12 211073 
rs6141600 20 C T 0.28 0.0003 0.035 0.005 3E-11 142740 
Chr: chromosome; EA: effect allele (trait-increasing allele); NEA: non-effect allele; R2: proportion of 
phenotypic variance explained by SNP; Beta: increase in standardized hip circumference per EA; SE: 
standard error; N: sample size.  
Supplementary Table 4 (continued) 
Supplementary Table 5. SNPs used as instrumental variables for adiponectin concentration in Mendelian 
randomisation analysis and association with adiponectin concentration 
rs ID Chr EA NEA EAF R2 Beta SE P-value N 
rs6810075 3 T C 0.63 0.0066 0.108 0.0078 4.E-41 29140 
rs16861209 3 A C 0.08 0.0125 0.313 0.0163 3.E-77 29199 
rs17366568 3 G A 0.91 0.0125 0.252 0.0142 3.E-66 24865 
rs3774261 3 A G 0.40 0.0080 0.114 0.0075 1.E-49 29081 
Chr: chromosome; EA: effect allele (trait-increasing allele); NEA: non-effect allele; R2: proportion of 
phenotypic variance explained by SNP; Beta: increase in standardized log adiponectin concentration per 
EA; SE: standard error; N: sample size. 
 Supplementary Table 6. Association of fat depots and adiponectin concentration with covariates according to sex 
  
Visceral fat 
Deep subcutaneous 
abdominal fat 
Superficial 
subcutaneous abdominal 
fat 
Gluteofemoral fat Adiponectin concentration 
  β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI 
 Males 
African ancestry (%)   
          
   
0.00-4.59 Ref   Ref   Ref   Ref   Ref   
4.60-10.99 0.01 -0.12 0.13 -0.02 -0.14 0.10 -0.03 -0.16 0.10 -0.09 -0.22 0.04 0.00 -0.13 0.14 
11.00-87.91 -0.11 -0.24 0.02 -0.19 -0.31 -0.07 -0.06 -0.18 0.07 -0.27 -0.40 -0.14 -0.12 -0.25 0.01 
Leisure-time physical activity               
Inactive Ref   Ref   Ref   Ref   Ref   
Insufficiently active -0.02 -0.15 0.11 -0.02 -0.15 0.11 -0.08 -0.22 0.05 -0.08 -0.22 0.06 0.04 -0.10 0.18 
Active -0.18 -0.30 -0.06 -0.10 -0.22 0.02 -0.09 -0.21 0.04 -0.13 -0.26 0.00 -0.07 -0.20 0.06 
Smoking                 
Never smoker Ref   Ref   Ref   Ref   Ref   
Ex-smoker 0.13 -0.01 0.27 -0.10 -0.24 0.03 -0.17 -0.31 -0.03 -0.05 -0.20 0.10 -0.04 -0.19 0.11 
1-9 cigarettes/day -0.04 -0.23 0.16 -0.33 -0.51 -0.14 -0.37 -0.57 -0.18 -0.39 -0.60 -0.19 0.00 -0.21 0.20 
≥ 10 cigarettes/day -0.03 -0.17 0.11 -0.39 -0.52 -0.26 -0.46 -0.59 -0.32 -0.40 -0.55 -0.26 0.04 -0.11 0.19 
Alcohol drinking                 
< 1 dose/day Ref   Ref   Ref   Ref   Ref   
≥ 1 dose/day 0.18 0.08 0.29 -0.03 -0.14 0.07 -0.09 -0.20 0.02 0.01 -0.11 0.12 0.00 -0.11 0.12 
  
 Females 
African ancestry (%)                
0.00-4.59 Ref   Ref   Ref   Ref   Ref   
4.60-10.99 0.06 -0.07 0.18 -0.06 -0.18 0.07 -0.02 -0.15 0.10 -0.13 -0.26 0.00 -0.13 -0.26 -0.01 
11.00-87.91 0.21 0.09 0.33 0.02 -0.10 0.15 0.10 -0.02 0.23 -0.03 -0.16 0.10 -0.27 -0.39 -0.14 
Leisure-time physical activity               
Inactive Ref   Ref   Ref   Ref   Ref   
Insufficiently active -0.21 -0.35 -0.07 0.02 -0.12 0.16 0.03 -0.11 0.17 -0.05 -0.19 0.10 0.02 -0.13 0.16 
Active -0.30 -0.42 -0.17 -0.08 -0.21 0.05 -0.10 -0.23 0.02 -0.07 -0.20 0.06 0.09 -0.04 0.22 
Smoking                 
Never smoker Ref   Ref   Ref   Ref   Ref   
Ex-smoker 0.07 -0.07 0.20 -0.02 -0.16 0.12 -0.03 -0.16 0.11 -0.08 -0.22 0.06 -0.11 -0.25 0.02 
1-9 cigarettes/day -0.04 -0.22 0.14 0.00 -0.18 0.19 -0.16 -0.34 0.02 -0.28 -0.47 -0.09 -0.14 -0.33 0.04 
≥ 10 cigarettes/day 0.15 0.00 0.31 -0.13 -0.29 0.03 -0.25 -0.40 -0.09 -0.31 -0.47 -0.15 -0.28 -0.43 -0.12 
Alcohol drinking                 
< 1 dose/day Ref   Ref   Ref   Ref   Ref   
≥ 1 dose/day -0.01 -0.12 0.09 0.04 -0.07 0.15 -0.04 -0.14 0.07 0.05 -0.06 0.16 0.06 -0.05 0.16 
Fat depots and adiponectin concentration are expressed as standard deviation units.
Supplementary Table 7. Pearson’s correlation coefficients between different measures of adiposity  
    BMI Total fat VAT dSCAAT  sSCAAT  GFAT 
M
A
L
E
 
BMI 1.00 0.89 0.67 0.66 0.60 0.84 
Total fat 0.89 1.00 0.62 0.75 0.71 0.97 
VAT 0.67 0.62 1.00 0.35 0.30 0.53 
dSCAAT  0.66 0.75 0.35 1.00 0.59 0.71 
sSCAAT  0.60 0.71 0.30 0.59 1.00 0.69 
GFAT 0.84 0.97 0.53 0.71 0.69 1.00 
F
E
M
A
L
E
 
BMI 1.00 0.94 0.63 0.71 0.66 0.89 
Total fat 0.94 1.00 0.55 0.73 0.68 0.97 
VAT 0.63 0.55 1.00 0.34 0.31 0.48 
dSCAAT  0.71 0.73 0.34 1.00 0.46 0.65 
sSCAAT  0.66 0.68 0.31 0.46 1.00 0.61 
GFAT 0.89 0.97 0.48 0.65 0.61 1.00 
BMI: body mass index; GFAT: gluteofemoral adipose tissue; dSCAAT: deep subcutaneous 
adipose tissue; sSCAAT: superficial subcutaneous adipose tissue; VAT: visceral adipose tissue. 
Data from the 2012 follow-up of the 1982 Pelotas Birth Cohort. 
  
Supplementary Table 8. P values for the association of study variables with missingness indicator 
  P values 
Variable Males Females 
African ancestry 0.13 0.64 
Leisure-time physical activity 0.10 0.02 
Smoking 0.47 0.48 
Alcohol drinking 0.03 0.70 
Body mass index 1*10-10 0.74 
Visceral fat 2*10-4 0.74 
Deep subcutaneous abdominal fat 3*10-5 0.72 
Superficial subcutaneous abdominal fat 0.01 0.41 
Gluteofemoral fat 0.16 0.34 
Adiponectin 0.80 0.67 
Glucose 0.12 0.83 
C reactive protein 0.16 0.19 
Data from the 2012 follow-up of the 1982 Pelotas Birth Cohort
 Supplementary Figure 1. Metanalysis and heterogeneity analysis of Mendelian randomization estimates 
of each SNP for the association of waist circumference with blood adiponectin levels. Data from GIANT 
(n = up to 210,088 individuals) and ADIPOGen (n = 29,347 individuals) consortia.
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 Supplementary Figure 2. Metanalysis and heterogeneity analysis of Mendelian randomization estimates 
of each SNP for the association of hip circumference with blood adiponectin levels. Data from GIANT 
(n = up to 210,088 individuals) and ADIPOGen (n = 29,347 individuals) consortia.
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 Supplementary Figure 3. Funnel plot of instrument precision (standard error of IVW estimate) against IVW estimates for each genetic variant for Mendelian randomization analysis of the 
influence of waist (A) or hip (B) circumference on adiponectin levels. Each blue dot corresponds to estimates of one genetic variant. Full vertical line represents the overall IVW estimate and 
dashed lines represent pseudo 95% confidence limits. Red line indicates the presence of asymmetry. IVW: inverse-variance weighted method. Data from GIANT (n = up to 210,088 individuals) 
and ADIPOGen (n = 29,347 individuals) consortia. 
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